-
公开(公告)号：US20180344850A1
公开(公告)日：2018-12-06
申请号：US15992852
申请日：2018-05-30
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Frederic A. BOURKE, JR. , Mark DEWHIRST , Neil SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA , Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Harold WALDER
摘要： A system (and associated method) for treating a human or animal body. The system has a photoactivatable drug for treating a first diseased site, a first pharmaceutically acceptable carrier including one or more phosphorescent or fluorescent agents which are capable of emitting an activation energy into the body which activates the photoactivatable drug, a first device which infuses the first diseased site with a photoactivatable drug and the first pharmaceutically acceptable carrier, a first energy source which irradiates the diseased site with an initiation energy to thereby initiate emission of the activation energy into the body, and a supplemental treatment device which administers one or both of a therapeutic drug or radiation to the body at a second diseased site or the first diseased site, to provide an immune system stimulation in the body.
-
2.发明申请公开(公告)号：US20170162537A1
公开(公告)日：2017-06-08
申请号：US15382835
申请日：2016-12-19
申请人： Immunolight, LLC , Duke University
IPC分类号： H01L23/00 , B32B37/12 , B32B37/18 , C09K11/77 , H01L25/00 , C09J133/08 , C09K11/02 , B32B38/00 , H01L25/065
CPC分类号： H01L24/83 , A61B17/0057 , A61L24/06 , B32B3/266 , B32B7/14 , B32B9/04 , B32B37/1284 , B32B37/18 , B32B38/0008 , B32B2037/1253 , B32B2457/00 , B32B2457/08 , B32B2457/14 , B41J2/17559 , C08K3/00 , C09J4/00 , C09J9/02 , C09J11/04 , C09J11/06 , C09J133/08 , C09K11/02 , C09K11/7769 , C09K11/777 , H01L23/5226 , H01L24/32 , H01L25/0657 , H01L25/50 , H01L2224/16225 , H01L2224/32225 , H01L2224/48091 , H01L2224/48227 , H01L2224/73204 , H01L2224/73253 , H01L2224/73265 , H01L2224/83192 , H01L2224/83855 , H01L2224/92125 , H01L2225/06524 , H01L2225/06589 , H01L2924/07811 , H01L2924/1461 , H01L2924/15311 , Y10T428/2852 , H01L2924/00014 , H01L2924/00
摘要： A polymerizable composition includes at least one monomer, a photoinitiator capable of initiating polymerization of the monomer when exposed to light, and a phosphor capable of producing light when exposed to radiation (typically X-rays). The material is particularly suitable for bonding components at ambient temperature in situations where the bond joint is not accessible to an external light source. An associated method includes: placing a polymerizable adhesive composition, including a photoinitiator and energy converting material, such as a down-converting phosphor, in contact with at least two components to be bonded to form an assembly; and, irradiating the assembly with radiation at a first wavelength, capable of conversion (down-conversion by the phosphor) to a second wavelength capable of activating the photoinitiator, to prepare items such as inkjet cartridges, wafer-to-wafer assemblies, semiconductors, integrated circuits, and the like.
-
公开(公告)号：US20220080045A1
公开(公告)日：2022-03-17
申请号：US17538770
申请日：2021-11-30
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Harold WALDER , Frederic A. BOURKE, JR. , Zakaryae FATHI , Wayne F. BEYER , Mark OLDHAM , Justus ADAMSON , Michael NOLAN
摘要： A method for treating a disease in a subject in need thereof is provided involving infusing 8-methoxypsoralen (8-MOP) and a phosphor-containing drug activator into a diseased site in the subject; and delivering a dose of x-rays to the subject for production of the ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose including a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor, wherein the phosphor-containing drug activator includes an admixture of two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays; the two or more phosphors including Zn2SiO4:Mn2+ and (3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+) at a ratio (Zn2SiO4:Mn2+):(3Ca3(PO4)2Ca(F, Cl)2: Sb3+, Mn2+)) of from 1:10 to 10:1; wherein each of the two or more phosphors have at least one coating selected from an ethyl cellulose coating or a diamond-like carbon coating.
-
公开(公告)号：US20200368547A1
公开(公告)日：2020-11-26
申请号：US16860623
申请日：2020-04-28
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Frederic A. BOURKE, JR. , Harold WALDER , Zakaryae FATHI , Michael J. THERIEN , Mark W. DEWHIRST , Ian N. STANTON , Jennifer Ann AYRES , Diane Renee FELS , Joseph A. HERBERT
摘要： A method for treating a disease, disorder, or condition in a subject in need thereof, by administering either or both of (i) at least one photoactivatable pharmaceutical agent, or (ii) a first plurality of energy-emitting particles, into the subject in a region of the disease, disorder, or condition, whereby the administering is performed through inhalation; and applying an applied electromagnetic energy to the subject, wherein the applied electromagnetic energy directly or indirectly activates the at least one photoactivatable pharmaceutical agent, when present, and wherein when the first plurality of energy-emitting particles is present, the first plurality of energy-emitting particles absorbs the applied energy and emits an emitted electromagnetic energy, wherein the emitted electromagnetic energy interacts directly with the region of the disease, disorder, or condition or activates the at least one photoactivatable pharmaceutical agent.
-
5.发明申请公开(公告)号：US20200282056A1
公开(公告)日：2020-09-10
申请号：US16074707
申请日：2017-02-02
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Harold WALDER , Frederic A. BOURKE, JR. , Zakaryae FATHI , Wayne BEYER , Mark OLDHAM , Justus ADAMSON , Michael NOLAN
摘要： A phosphor-containing drug activator and suspension thereof are provided. The suspension at least includes two or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays. The two or more phosphors include Zn2SiO4:M12+ and (3Ca3 (PO4)2Ca(F, Cl)2:Sb3*, Mn2+) at a ratio NP-200:GTP-4300 of from 1:10 to 10:1, and each of the two phosphors have an ethylene cellulose coating and/or a diamond-like carbon coating. The suspension further includes a pharmaceutically acceptable carrier. A system for treating a disease in a subject in need thereof includes a) the above-noted suspension, b) a photoactivatable drug containing 8-methoxypsoralen (8-MOP or UVADEX) untethered from the two or more phosphors, c) one or more devices which infuse the photoactivatable drug and the suspension including the pharmaceutically acceptable carrier into a diseased site in the subject, and d) an x-ray source which is controlled to deliver a dose of x-rays to the subject for production of the ultraviolet light.
-
公开(公告)号：US20220062419A1
公开(公告)日：2022-03-03
申请号：US17227753
申请日：2021-04-12
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark OLDHAM , Justus ADAMSON , Mark W. DEWHIRST , Paul YOON , Harold WALDER , Frederic A. Bourke, JR. , Zakaryae FATHI , Wayne F. BEYER, JR.
IPC分类号： A61K41/00 , A61N5/06 , A61K31/655 , A61K33/02 , A61K31/409 , A61K31/525 , A61K31/352 , A61K31/403 , A61K33/242 , A61K33/244 , A61K33/24 , A61N5/10
摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
-
公开(公告)号：US20200009398A1
公开(公告)日：2020-01-09
申请号：US16554831
申请日：2019-08-29
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Frederic A. BOURKE, JR. , Harold WALDER , Mark DEWHIRST , Neil L. SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA
IPC分类号： A61N5/06 , A61K31/352 , A61K41/00
摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
公开(公告)号：US20190184190A1
公开(公告)日：2019-06-20
申请号：US16322178
申请日：2017-08-01
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Harold WALDER , Frederic A. BOURKE , Zakaryae FATHI , Wayne BEYER , Mark OLDHAM , Justus ADAMSON , Paul YOON
CPC分类号： A61N5/062 , A61K33/42 , A61K41/00 , A61K41/0057 , A61N5/10 , A61N2005/1098 , A61P35/00
摘要： A phosphor-containing drug activator activatable from a Monte Carlo derived x-ray exposure for treatment of a diseased site. The activator includes an admixture or suspension of one or more phosphors capable of emitting ultraviolet and visible light upon interaction with x-rays, wherein a distribution of the phosphors in the diseased target site is based on a Monte Carlo derived x-ray dose distribution. A system for treating a disease in a subject in need thereof, includes the drug activator and a photoactivatable drug, one or more devices which infuse the photoactivatable drug and the activator including the pharmaceutically acceptable carrier into a diseased site in the subject; and an x-ray source which is controlled to deliver the Monte Carlo derived x-ray exposure to the subject for production of ultraviolet and visible light inside the subject to activate the photoactivatable drug and induce a persistent therapeutic response, the dose comprising a pulsed sequence of x-rays delivering from 0.5-2 Gy to the tumor.
-
公开(公告)号：US20180311355A1
公开(公告)日：2018-11-01
申请号：US15770926
申请日：2016-10-26
申请人： IMMUNOLIGHT, LLC. , DUKE UNIVERSITY
发明人： Mark OLDHAM , Justus ADAMSON , Mark W. DEWHIRST , Paul YOON , Harold WALDER , Frederic A. BOURKE , Zakaryae FATHI , Wayne F. BEYER
CPC分类号： A61K31/655 , A61K31/352 , A61K31/403 , A61K31/409 , A61K31/525 , A61K33/02 , A61K41/0066 , A61N5/062 , A61N5/0624 , A61N2005/065 , A61N2005/1095 , A61N2005/1098 , Y02A50/393
摘要： A method and system for treating a subject with a disorder which provides within the subject at least one photoactivatable drug for treatment of the subject, applies initiation energy from at least one source to generate inside the subject a preferential x-ray flux for generation of Cherenkov radiation (CR) light capable of activating at least one photoactivatable drug, and from the CR light, activating inside the subject the at least one photoactivatable drug to thereby treat the disorder.
-
公开(公告)号：US20170157418A1
公开(公告)日：2017-06-08
申请号：US15434871
申请日：2017-02-16
申请人： IMMUNOLIGHT, LLC , DUKE UNIVERSITY
发明人： Mark OLDHAM , Zakaryae FATHI , Wayne F. BEYER , Harold WALDER , Frederic A. BOURKE, JR. , Mark DEWHIRST , Neil L. SPECTOR , Paul YOON , Justus ADAMSON , David ALCORTA , Kim LYERLY , Leihua LIU , Takuya OSADA
IPC分类号： A61N5/06 , A61K31/352 , A61K41/00 , A61N5/10
CPC分类号： A61N5/062 , A61K31/352 , A61K31/525 , A61K33/00 , A61K35/00 , A61K38/00 , A61K41/0066 , A61N5/10 , A61N2005/0661 , A61N2005/0662 , A61N2005/1089 , A61N2005/1098
摘要： A system for treating a diseased site in a human or animal body. The system includes a pharmaceutical carrier including one or more phosphors which are capable of emitting light into the diseased site upon interaction, a photoactivatable drug for intercalating into DNA of cells at the diseased site, one or more devices which infuse the diseased sited with the photoactivatable drug and the pharmaceutical carrier, an x-ray or high energy electron source, and a processor programmed to control a dose of x-rays or electrons to the diseased site for production of light inside the tumor to activate the photoactivatable drug.
-
-
-
-
-
-
-
-
-
搜索结果
41 条记录 (耗时 0.021 秒)